Nuvectis Pharma Inc (NVCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nuvectis Pharma Inc (NVCT) has a cash flow conversion efficiency ratio of -0.187x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.49 Million) by net assets ($24.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Nuvectis Pharma Inc net asset quality index to measure how much of total assets are equity-financed.
Nuvectis Pharma Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Nuvectis Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Nuvectis Pharma Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Nuvectis Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvectis Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TCI Express Limited
NSE:TCIEXP
|
0.026x |
|
BF Utilities Limited
NSE:BFUTILITIE
|
0.229x |
|
All Iron Re I Socimi Sa
MC:YAI1
|
0.053x |
|
FG Imperii Acquisition Corp. Class A Ordinary Shares
NASDAQ:FGII
|
0.006x |
|
ProKidney Corp.
NASDAQ:PROK
|
-0.108x |
|
Polaris Infrastructure Inc
TO:PIF
|
0.035x |
|
Villeroy & Boch AG
XETRA:VIB3
|
0.066x |
|
Fujian Fynex Textile Science & Technology Co Ltd
SHG:600493
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Nuvectis Pharma Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Nuvectis Pharma Inc from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see Nuvectis Pharma Inc (NVCT) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.71 Million | $-12.25 Million | -1.261x | +3.57% |
| 2023-12-31 | $12.20 Million | $-15.95 Million | -1.308x | -37.12% |
| 2022-12-31 | $14.22 Million | $-13.56 Million | -0.954x | -210.45% |
| 2021-12-31 | $-11.01 Million | $-9.50 Million | 0.863x | +23811.81% |
| 2020-12-31 | $6.65 Million | $24.00K | 0.004x | -- |
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also dev… Read more